symdeko drive sale pivot triplerx data trim
cf sale beat due continu symdeko uptak sale
cannib orkambi kalydeco sale consensu
vertex maintain cf sale guidanc continu forecast
non-gaap dilut ep beat symkevi approv europ expect
quarter primari driver triplerx data two phase studi late
parallel studi vertex file nda best regimen
approv like partner crispr commenc beta-
thal studi europ begin sickl cell diseas studi
reiter ow rate howev trim pt lower
price-to-earnings multipl due market condit potenti cf competit
symdeko launch drive symdeko continu see rapid uptak
million sale qoq cannib orkambi continu sale
million major patient start symdeko
receiv prior cftr modul therapi homozyg patient
discontinu orkambi kalydeco sale million consensu
may driven residu function start transit orkambi total
cf franchis remain strong sale million beat estim
vertex maintain cf sale guidanc billion continu
forecast billion year anticip symkevi european approv
quarter vertex continu secur reimburs agreement furthermor label
expans kalydeco come snda file late residu
function mutat pediatr european approv infant look
orkambi label expans next year pediatr europ well
triplerx data lead nda enrol two pivot phase trial
plu symdeko het/min homozyg patient complet
data expect quarter parallel trial expect complet
enrol quarter readout vertex intend file nda
base efficaci safeti data could result approv
first cf triplerx regimen vertex also initi triplerx studi
children age year homozyg heterozyg
crispr develop partner crispr advanc phase i/ii sickl
cell diseas scd studi follow lift fda ind hold multipl
clear europ beta-thalassemia phase i/ii studi open enrol
patient across multipl clinic site
cf drug may fail clinic gain approv may meet expect
vertex biopharmaceut compani develop innov drug
thru
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
good sold
royalti payment
thousand except per share data
net incom loss attribut allio
compani report piper jaffray co analysi
current disclosur inform compani found
